ELISA Methods Developed for Analyzing Immunotherapy
By LabMedica International staff writers Posted on 06 Mar 2018 |
Image: Bevacizumab (Avastin) is approved for immunotherapy use in metastatic renal cell carcinoma, glioblastoma, non-squamous non–small-cell lung cancer, and metastatic colorectal cancer, and cervical cancer (Photo courtesy of Genentech).
A new enzyme-linked immunosorbent assay (ELISA) with high sensitivity and selectivity for bioanalysis of bevacizumab (BEV), a monoclonal antibody used for immunotherapy of different types of cancer, has been developed.
Bevacizumab is a recombinant humanized monoclonal antibody directed against the vascular endothelial growth factor (VEGF), a pro-angiogenic cytokine. Bevacizumab binds to VEGF and inhibits VEGF receptor binding, thereby preventing the growth and maintenance of tumor blood vessels.
Scientists at King Saud University (Riyadh, Saudi Arabia) captured BEV by specific antigen human vascular endothelial growth factor protein; (VEGF) immobilized onto a 96-well assay plate. The BEV-VEGF complex formed onto the plate wells were quantified using horseradish peroxidase labeled anti-human immunoglobulin-G (HRP-IgG) and 3,3`,5,5`-tetramethylbenzidine (TMB) as a chromogenic substrate for peroxidase enzyme.
The optimum conditions for conducting the proposed ELISA were established and its analytical performance was evaluated as per the guidelines for the validation of immunoassays for bioanalysis of therapeutic monoclonal antibody. The assay limit of detection was 1.01 ng /mL and the effective working dynamic range was 3.07 to100 ng/mL. The accuracy and precision of the assay were proven. The present assay with high throughput analysis was very easy to perform in a 96-well plate and permits an operator to analyze a batch of about 200 samples, in triplicate. This facilitates the processing of a large number of samples in a clinical setting. ELISA eliminated the need for pretreatment of plasma samples by affinity chromatography or other sophisticated equipment.
The authors have also developed a similar assay for cetuximab (CET) in human plasma samples. CET was captured by specific epidermal growth factor receptor (EGFR) antigen protein immobilized onto a 96-well assay plate. The CET- EGFR complex formed onto the plate wells were quantified using alkaline phosphatase enzyme labeled anti-human IgG (ALP-IgG) and para-nitrophenyl phosphate substrate (pNPP) as a chromogenic substrate for alkaline phosphatase enzyme. The assay limit of detection was 1.5 ng/mL and the effective working dynamic range was 0.005-6.25 μg/mL. The studies were published on January 31, 2018, in the journal Current Pharmaceutical Analysis.
Related Links:
King Saud University
Bevacizumab is a recombinant humanized monoclonal antibody directed against the vascular endothelial growth factor (VEGF), a pro-angiogenic cytokine. Bevacizumab binds to VEGF and inhibits VEGF receptor binding, thereby preventing the growth and maintenance of tumor blood vessels.
Scientists at King Saud University (Riyadh, Saudi Arabia) captured BEV by specific antigen human vascular endothelial growth factor protein; (VEGF) immobilized onto a 96-well assay plate. The BEV-VEGF complex formed onto the plate wells were quantified using horseradish peroxidase labeled anti-human immunoglobulin-G (HRP-IgG) and 3,3`,5,5`-tetramethylbenzidine (TMB) as a chromogenic substrate for peroxidase enzyme.
The optimum conditions for conducting the proposed ELISA were established and its analytical performance was evaluated as per the guidelines for the validation of immunoassays for bioanalysis of therapeutic monoclonal antibody. The assay limit of detection was 1.01 ng /mL and the effective working dynamic range was 3.07 to100 ng/mL. The accuracy and precision of the assay were proven. The present assay with high throughput analysis was very easy to perform in a 96-well plate and permits an operator to analyze a batch of about 200 samples, in triplicate. This facilitates the processing of a large number of samples in a clinical setting. ELISA eliminated the need for pretreatment of plasma samples by affinity chromatography or other sophisticated equipment.
The authors have also developed a similar assay for cetuximab (CET) in human plasma samples. CET was captured by specific epidermal growth factor receptor (EGFR) antigen protein immobilized onto a 96-well assay plate. The CET- EGFR complex formed onto the plate wells were quantified using alkaline phosphatase enzyme labeled anti-human IgG (ALP-IgG) and para-nitrophenyl phosphate substrate (pNPP) as a chromogenic substrate for alkaline phosphatase enzyme. The assay limit of detection was 1.5 ng/mL and the effective working dynamic range was 0.005-6.25 μg/mL. The studies were published on January 31, 2018, in the journal Current Pharmaceutical Analysis.
Related Links:
King Saud University
Latest Immunology News
- Diagnostic Blood Test for Cellular Rejection after Organ Transplant Could Replace Surgical Biopsies
- AI Tool Precisely Matches Cancer Drugs to Patients Using Information from Each Tumor Cell
- Genetic Testing Combined With Personalized Drug Screening On Tumor Samples to Revolutionize Cancer Treatment
- Testing Method Could Help More Patients Receive Right Cancer Treatment
- Groundbreaking Test Monitors Radiation Therapy Toxicity in Cancer Patients
- State-Of-The Art Techniques to Investigate Immune Response in Deadly Strep A Infections
- Novel Immunoassays Enable Early Diagnosis of Antiphospholipid Syndrome
- New Test Could Predict Immunotherapy Success for Broader Range Of Cancers
- Simple Blood Protein Tests Predict CAR T Outcomes for Lymphoma Patients
- Cell Sorter Chip Technology to Pave Way for Immune Profiling at POC
- Chip Monitors Cancer Cells in Blood Samples to Assess Treatment Effectiveness
- Automated Immunohematology Approaches Can Resolve Transplant Incompatibility
- AI Leverages Tumor Genetics to Predict Patient Response to Chemotherapy
- World’s First Portable, Non-Invasive WBC Monitoring Device to Eliminate Need for Blood Draw
- Predictive T-Cell Test Detects Immune Response to Viruses Even Before Antibodies Form
- Single Blood Draw to Detect Immune Cells Present Months before Flu Infection Can Predict Symptoms